Effectiveness of leech therapy in osteoarthritis of the thumb carpometacarpal joint: a randomized controlled trial
Michalsen A, Lüdtke R, Cesur Ö, Afra D, Musial F, Baecker M, Dobos GJ (2008) · Pain · n=32
Perfil del estudio
- Diseño
- single-center, open-label, randomized controlled trial (Essen)
- Tamaño de la muestra (n)
- 32
- Intervención
- Single session of 2-4 Hirudo medicinalis leeches applied around the symptomatic CMC-1 joint, 60-80 minutes
- Comparador
- Topical diclofenac gel applied 3 times daily for 30 days plus standardized hand exercise booklet
- Punto final primario
- Pain intensity on 100mm VAS at day 7
- Resultado primario
- VAS pain dropped from 60.8mm to 25.3mm in leech group vs 56.4mm to 49.5mm in diclofenac group at day 7 (between-group difference 24.2mm, p<0.001); effect maintained at day 30
- Effect size (Cohen's d)
- 1.2
- Duración del seguimiento
- 60 days
- PMID
- 18407413
Hallazgos clave
- First RCT of hirudotherapy for thumb carpometacarpal osteoarthritis
- Effect size (Cohen's d ≈ 1.2) comparable to the same group's knee OA RCT (Michalsen 2003)
- Functional improvement on DASH (Disabilities of the Arm, Shoulder and Hand) significant at days 7, 30, 60
- Patients reported improved pinch grip strength on dynamometry
- Only 2-4 leeches required per session at this smaller joint — lower cost and shorter session than knee protocol
Limitaciones
- Small sample (n=32) — single-site pilot
- Open-label, no sham control
- Restricted to advanced (Eaton stage II-III) CMC-1 OA — milder disease untested
- No imaging endpoint to confirm anatomical durability
- Comparator gel may underestimate effect of oral NSAIDs or splinting
Implicaciones clínicas
Michalsen 2008 extended hirudotherapy efficacy from the large weight-bearing joint (knee) to a small non-weight-bearing joint (CMC-1 thumb), demonstrating that the effect is not unique to load-bearing structures. CMC-1 OA is notoriously refractory to conservative management — most patients progress to corticosteroid injection or arthroplasty. A non-surgical, non-injection option with this effect size is clinically valuable, especially for early-stage Eaton II disease. The trial is the foundational evidence for the second-most-common ASH clinical indication after knee OA.
Estudios relacionados
Leech therapy versus topical diclofenac for thumb carpometacarpal osteoarthritis: a randomized pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R (2008)
Conservative treatment of thumb base osteoarthritis: a systematic review
Spaans AJ, van Minnen LP, Kon M, Schuurman AH, Schreuders AR, Vermeulen GM (2015)